keyword
MENU ▼
Read by QxMD icon Read
search

Small lymphocytic lymphoma

keyword
https://www.readbyqxmd.com/read/29661716/small-cell-lymphocytic-variant-of-marginal-zone-lymphoma-a-distinct-form-of-marginal-zone-lymphoma-derived-from-na%C3%A3-ve-b-cells-as-a-cutaneous-counterpart-to-the-na%C3%A3-ve-marginal-zone-lymphoma-of-splenic-origin
#1
REVIEW
Cynthia M Magro, Luke C Olson
Primary cutaneous marginal zone lymphoma most commonly represents an indolent form of cutaneous B cell lymphoma. However, epidermotropic marginal zone lymphoma, blastic marginal zone lymphoma and B cell dominant variants without isotype switching can be associated with extracutaneous dissemination. The presumptive cell of origin is a post germinal center B cell with plasmacytic features. In the extracutaneous setting, however, a naïve B cell origin has been proposed for a subset of marginal zone lymphomas, notably splenic marginal zone lymphoma...
February 21, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29659938/mutual-risks-of-cutaneous-melanoma-and-specific-lymphoid-neoplasms-second-cancer-occurrence-and-survival
#2
Megan M Herr, Sara J Schonfeld, Graça M Dores, Diana R Withrow, Margaret A Tucker, Rochelle E Curtis, Lindsay M Morton
Background: It is unclear whether the established association between cutaneous melanoma (CM) and lymphoid neoplasms (LNs) differs across LN subtypes. This study quantifies risk for developing CM after specific LNs and, conversely, for developing specific LNs after CM, as well as assessing clinical impact. Methods: We identified a cohort of Caucasian adults (age 20-83 years) initially diagnosed with CM or LN, as reported to 17 US population-based cancer registries, 2000-2014...
April 6, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29657256/colonal-monomorphic-epitheliotropic-intestinal-t-cell-lymphoma-with-novel-phenotype-of-cytoplasmic-cd3-expression
#3
Yumi Aoyama, Hiroko Tsunemine, Yuriko Zushi, Hayato Maruoka, Yuta Goto, Taiichi Kodaka, Tomoo Itoh, Takayuki Takahashi
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a new clinical entity that was reclassified from enteropathy-associated T-cell lymphoma in the 2016 WHO classification. An 83-year-old man with fever and diarrhea was referred to our hospital because of free air in the abdominal cavity and wall thickening of the large intestine on CT. Colonofiberscopic examination revealed mucosal edema and multiple ulcers at the sigmoid colon, splenic flexure, and transverse colon. Histopathological examination of the mucosal biopsy specimen demonstrated dense infiltration of small lymphocytes with nuclear atypia, some of which exhibited intraepithelial invasion...
April 13, 2018: Journal of Clinical and Experimental Hematopathology: JCEH
https://www.readbyqxmd.com/read/29651368/synchronous-pulmonary-neoplasms-a-chance-occurrence-or-is-there-more-than-meets-the-eye
#4
Uroosa Ibrahim, Amina Saqib, Manisha Pant, Gwenalyn Garcia, Marcel Odaimi
Primary bronchus-associated lymphoid tissue (BALT) lymphoma comprises 5% of non-Hodgkin's lymphoma (NHL) and usually has an indolent course. Synchronous primary lung cancers with BALT lymphoma are seldom seen in patients with adenocarcinoma of the lung. Synchronous squamous cell carcinoma (SCC) and BALT lymphoma is an extremely rare occurrence. We report an unusual case of stage 4 BALT lymphoma requiring treatment that revealed an underlying ipsilateral mass causing a diagnostic dilemma. An 84-year-old female with a history of systemic lupus erythematosus, deep vein thrombosis, and thrombotic microangiopathy presented to the hospital with cough and dyspnea on exertion...
February 6, 2018: Curēus
https://www.readbyqxmd.com/read/29620207/calotropin-regulates-the-apoptosis-of-non%C3%A2-small-cell-cancer-by-regulating-the-cytotoxic-t%C3%A2-lymphocyte-associated-antigen-4%C3%A2-mediated-tgf%C3%A2-%C3%AE-erk-signaling-pathway
#5
Lu Tian, Xiao-Hong Xie, Ze-Hao Zhu
Non‑small‑cell lung cancer (NSCLC) is one of the most common malignancies that is responsible for a high level of cancer‑associated mortalities worldwide. Previous evidence has shown that Calotropin is an upstream activator of protein kinase B, which can further inhibit the growth and promote the apoptosis of NSCLC cells. In the present study, the efficacy of Calotropin on growth, aggressiveness and apoptosis of NSCLC cells was investigated, as well as the potential underlying mechanism. The results demonstrated that Calotropin inhibited H358 cell growth, migration and invasion...
April 5, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29618685/-splenic-diffuse-red-pulp-small-b-cell-lymphoma-diagnosed-by-splenectomy-initially-mimicking-hairy-cell-leukemia-japanese-variant
#6
Yukika Yamada, Miyoko Miura, Mayu Tagari, Kazuo Oshimi, Tomokazu Shiragata, Wataru Suga, Tatsurou Takahashi, Kazuyoshi Shimizu, Kouichi Ohshima, Keizou Kajiwara
A 62-year-old man presented to the hospital with thrombocytopenia, and splenomegaly was detected. His blood films prepared by natural air drying revealed medium-sized lymphocytes with unevenly distributed large and small villous projections. The cytoplasm was basophilic, nuclei were oval with clumped chromatin, and nucleoli were absent in most cells. Immune phenotypes CD19+, CD20+, CD11c+, FMC7+, IgM+, and Igκ+ were detected. TRAP stain appeared negative, IgH JH chain genes were monoclonally rearranged, and BRAF V600E mutation was not detected...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29608241/an-analysis-of-the-effect-of-statins-on-the-risk-of-non-hodgkin-s-lymphoma-in-the-women-s-health-initiative-cohort
#7
Pinkal Desai, Robert Wallace, Matthew L Anderson, Barbara V Howard, Roberta Ray, Chunyuan Wu, Monika Safford, Lisa W Martin, Nicolas Schlecht, Simin Liu, Dominic Cirillo, Allison Jay, JoAnn E Manson, Michael S Simon
Statins have been shown to induce a phosphoprotein signature that modifies MYC (myelocytomatosis viral oncogene) activation and to have anti-inflammatory activity that may impact the risk of Non-Hodgkin's lymphoma (NHL). We analyzed the relationship between statins and risk of NHL using data from the Women's Health Initiative (WHI). The study population included 161,563 postmenopausal women ages 50-79 years from which 712 cases of NHL were diagnosed after 10.8 years of follow-up. Information on statin use and other risk factors was collected by self- and interviewer-administered questionnaires...
April 2, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29564725/occult-cardiac-lymphoma-and-sudden-death
#8
Kelly Olds, Karen Heath, John Miliauskas, Roger W Byard
A 56-year-old man with no previous medical history collapsed and was not able to be resuscitated. The major findings at autopsy were enlargement of the heart (weight = 527 g) which contained an infiltrating firm, homogeneous tumor in an epicardial location adjacent to the left anterior descending and right coronary arteries, with further extension into the right ventricular outflow tract, the interventricular septum and left ventricular free wall. Sections showed sheets of small lymphoid cells with scattered large lymphocytes amounting to a low-grade follicular non-Hodgkin lymphoma, as tumor cells were CD20, CD10, Bcl 2 and LMO 2 positive...
March 22, 2018: Forensic Science, Medicine, and Pathology
https://www.readbyqxmd.com/read/29563728/aggressive-angioimmunoblastic-t-cell-lymphomas-aitl-with-soft-tissue-extranodal-mass-varied-histopathological-patterns-with-peripheral-blood-bone-marrow-and-splenic-involvement-and-review-of-literature
#9
Tanushri Mukherjee, Rajat Dutta, S Pramanik
Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T cell non-Hodgkin lymphoma with an aggressive fatal course and it has varied clinical presentation with an uncommon presentation when they present as soft tissue masses or when there is spill in the peripheral blood or there are composite lymphomas that are rare presentations. Common presentations include lymphadenopathy, fever and systemic symptoms, hemolytic anemias, skin rashes, and rheumatoid arthritis. The classical histopathology is absence of follicles in lymph nodes with presence of high endothelial venules and the tumor cells of small to medium-sized lymphocytes with pale cytoplasm mixed with reactive T cells...
March 2018: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29552367/a-case-of-chemotherapy-refractory-thrlbcl-like-transformation-of-nlphl-successfully-treated-with-lenalidomide
#10
Mamatha Siricilla, Lydia Irwin, Andres Ferber
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of nonclassical Hodgkin lymphoma (HL). It resembles non-Hodgkin lymphoma (NHL), by expressing classic B cell markers such as CD20 and CD79a however lacks definitive HL markers (such as CD15 and CD30). T cell histiocyte-rich large B cell lymphoma (THRLBCL), on the other hand, is a distinct entity classified under NHL and considered a variant of diffuse large B cell lymphoma (DLBCL). NLPHL can look morphologically and immunologically similar to THRLBCL and often poses a diagnostic challenge...
2018: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/29550382/voxtalisib-xl765-in-patients-with-relapsed-or-refractory-non-hodgkin-lymphoma-or-chronic-lymphocytic-leukaemia-an-open-label-phase-2-trial
#11
Jennifer R Brown, Mehdi Hamadani, John Hayslip, Ann Janssens, Nina Wagner-Johnston, Oliver Ottmann, Jon Arnason, Hervé Tilly, Michael Millenson, Fritz Offner, Nashat Y Gabrail, Siddhartha Ganguly, Sikander Ailawadh, Siddha Kasar, Arnon P Kater, Jeanette K Doorduijn, Lei Gao, Joanne J Lager, Bin Wu, Coumaran Egile, Marie José Kersten
BACKGROUND: Patients with relapsed or refractory lymphoma or chronic lymphocytic leukaemia have a poor prognosis. Therapies targeting more than one isoform of PI3K, as well as mTOR, might increase antitumour activity. We aimed to investigate the efficacy and safety of voxtalisib (also known as XL765 or SAR245409), a pan-PI3K/mTOR inhibitor, in patients with relapsed or refractory lymphoma, or chronic lymphocytic leukaemia/small lymphocytic lymphoma. METHODS: We did a non-randomised, open-label, phase 2 trial at 30 oncology clinics in the USA, Belgium, Germany, France, the Netherlands, and Australia...
March 14, 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29549514/bone-loss-and-hematological-malignancies-in-adults-a-pilot-study
#12
Rosa Ruchlemer, Michal Amit-Kohn, Ariella Tvito, Irena Sindelovsky, Ari Zimran, David Raveh-Brawer
PURPOSE: Bone loss-osteopenia and osteoporosis-is a recognized consequence of solid tumors in adults, of pediatric hematological malignancies, and of the treatment for these diseases, but little research has been published on the adverse effects of hematological malignancies on the bone in adults. The aim of this study is to identify hematological diseases that are associated with the highest prevalence and severity of osteoporosis. METHODS: We evaluated DXA (dual-energy X-ray absorptiometry) in a cross-section of 181 adult patients with hematological neoplasms, excluding multiple myeloma...
March 16, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29533000/ibrutinib-versus-rituximab-in-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-a-randomized-open-label-phase-3-study
#13
Xiaojun Huang, Lugui Qiu, Jie Jin, Daobin Zhou, Xiequn Chen, Ming Hou, Jianda Hu, Yu Hu, Xiaoyan Ke, Junmin Li, Yingmin Liang, Ting Liu, Yue Lv, Hanyun Ren, Aining Sun, Jianmin Wang, Chunting Zhao, Mariya Salman, Steven Sun, Angela Howes, Jingzhao Wang, Peng Wu, Jianyong Li
In the Asia-Pacific region, treatment options are limited for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Rituximab is widely used in this setting when purine analog-based therapies are not appropriate. We evaluated the efficacy and safety of ibrutinib compared with rituximab in a randomized, open-label phase 3 study in predominantly Asian patients with relapsed/refractory CLL/SLL. Patients (N = 160) were randomly assigned 2:1 to receive 420 mg ibrutinib (n = 106) until disease progression (PD) or unacceptable toxicity or up to six cycles of rituximab (n = 54)...
March 13, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29532605/hepatitis-b-virus-and-risk-of-non-hodgkin-lymphoma-an-updated-meta-analysis-of-58-studies
#14
Mengge Li, Yu Gan, Chunsun Fan, Hui Yuan, Xianjing Zhang, Yuling Shen, Qing Wang, Zihong Meng, Dengfei Xu, Hong Tu
Previous studies have focused on the relationship between hepatitis B virus (HBV) infection and non-Hodgkin lymphoma (NHL). However, the results remain inconsistent and somehow conflicting in different sub-groups. The aim of this study was to combine the findings of independent studies to comprehensively assess the association between HBV and NHL using a meta-analysis. Relevant studies were identified through structured keyword searches in PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) database and 58 studies with a total of 53,714 NHL cases and 1,778,591 controls were finally included...
March 13, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29526963/paraneoplastic-pemphigus-associated-with-b-cell-chronic-lymphocytic-leukemia-treated-with-ibrutinib-and-rituximab
#15
Yuta Ito, Shinichi Makita, Akiko Miyagi Maeshima, Shunsuke Hatta, Tomotaka Suzuki, Sayako Yuda, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Koji Izutsu
Paraneoplastic pemphigus (PNP) is a severe autoimmune blistering disease associated with an underlying malignancy, and its prognosis is poor. We herein report the first patient with B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL)-associated PNP successfully treated with the Bruton's tyrosine kinase inhibitor ibrutinib and rituximab. Although his PNP lesions did not improve with ibrutinib monotherapy, the combination of ibrutinib and rituximab was effective against B-CLL/SLL-associated PNP...
March 9, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29520705/targeting-bcl-2-in-hematologic-malignancies
#16
Nadia Khan, Brad Kahl
Resistance to apoptosis is one of the hallmarks of cancer and members of the B-cell lymphoma 2 (BCL-2) family of proteins are central regulators of apoptosis. Many cancers become resistant to chemotherapy and apoptosis by up-regulating BCL-2 and other family members, making these proteins attractive targets for cancer therapy. Venetoclax is an orally administered, small-molecule apoptosis stimulant that targets BCL-2 proteins by acting as a BCL-2 homology domain 3 (BH3) mimetic. The drug is approved in the USA and EU as a monotherapy for the for the treatment of certain patients with chronic lymphocytic leukemia (CLL) and is in phase III clinical development for multiple myeloma (MM), and in phase II or I/II clinical trials for acute myeloid leukemia, and several B-cell malignancies, including diffuse large B-cell lymphoma, Waldenstrom's macroglobulinaemia, follicular lymphoma, and mantle-cell lymphoma...
March 8, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29516667/effusion-based-lymphoma-with-morphological-regression-but-with-clonal-genetic-features-after-aspiration
#17
Meng-Chen Tsai, Chun-Chi Kuo, Ying-Zhen Su, Yen-Chuan Hsieh, Shih-Sung Chuang
Effusion-based lymphoma (EBL) is a rare but distinct entity of large B-cell lymphoma in effusion without association with human herpes virus-8 (HHV-8). Spontaneous regression after pleurocentesis has been observed; but to our knowledge, there are no reports on the morphological and molecular features of subsequent aspirations in regressing cases. Here, we report the case of a 92-year-old male with chronic obstructive pulmonary disease, who presented with right pleural effusion. He had no human immunodeficiency virus, hepatitis B virus, or hepatitis C virus infection, and CT scans revealed no mass lesion...
March 8, 2018: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/29510739/measuring-multiple-parameters-of-cd8-tumor-infiltrating-lymphocytes-in-human-cancers-by-image-analysis
#18
Keith E Steele, Tze Heng Tan, René Korn, Karma Dacosta, Charles Brown, Michael Kuziora, Johannes Zimmermann, Brian Laffin, Moritz Widmaier, Lorenz Rognoni, Ruben Cardenes, Katrin Schneider, Anmarie Boutrin, Philip Martin, Jiping Zha, Tobias Wiestler
BACKGROUND: Immuno-oncology and cancer immunotherapies are areas of intense research. The numbers and locations of CD8+ tumor-infiltrating lymphocytes (TILs) are important measures of the immune response to cancer with prognostic, pharmacodynamic, and predictive potential. We describe the development, validation, and application of advanced image analysis methods to characterize multiple immunohistochemistry-derived CD8 parameters in clinical and nonclinical tumor tissues. METHODS: Commercial resection tumors from nine cancer types, and paired screening/on-drug biopsies of non-small-cell lung carcinoma (NSCLC) patients enrolled in a phase 1/2 clinical trial investigating the PD-L1 antibody therapy durvalumab (NCT01693562), were immunostained for CD8...
March 6, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29500171/management-of-relapsed-refractory-classical-hodgkin-lymphoma-in-transplant-ineligible-patients
#19
Neha Mehta-Shah, Nancy L Bartlett
Addition of brentuximab vedotin, a CD30 targeted antibody-drug conjugate, and the PD-1 inhibitors, nivolumab and pembrolizumab, to the armamentarium for transplant-ineligible relapsed/refractory classical Hodgkin lymphoma has resulted in improved outcomes, including the potential for cure in a small minority of patients. For patients who have failed prior transplant or are unsuitable for dose-intense approaches based on age or comorbidities, an individualized approach with sequential use of single agents such as brentuximab vedotin, PD-1 inhibitors, everolimus, lenalidomide, or conventional agents such as gemcitabine or vinorelbine, may result in prolonged survivals with minimal or modest effect on quality of life...
March 2, 2018: Blood
https://www.readbyqxmd.com/read/29483496/comparison-of-chromosomal-rearrangements-in-bone-marrow-cells-and-blast-transformed-b-cells-in-relapse-of-b-cell-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma
#20
S V Andreieva, K V Korets, O E Ruzhinska, I M Skorokhod, O G Alkhimova
AIM: The genetic mechanisms of resistance to chemotherapy in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) are not clear. We aimed to determine the peculiarities of abnormal karyotype formation in bone marrow (BM) cells and peripheral blood (PB) blast transformed B-cells in relapse of B-CLL/SLL. MATERIALS AND METHODS: Cytogenetic GTG banding technique and molecular cytogenetic in interphase cells (i-FISH) studies of BM cells and PB blast transformed B-lymphocytes were performed in 14 patients (10 males and 4 females) with B-CLL/SLL...
July 2017: Experimental Oncology
keyword
keyword
39628
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"